SG Americas Securities LLC Increases Stake in Bristol Myers Squibb Company $BMY

SG Americas Securities LLC raised its stake in Bristol Myers Squibb Company (NYSE:BMY) by 153.8% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 8,910,032 shares of the biopharmaceutical company’s stock after purchasing an additional 5,399,407 shares during the quarter. Bristol Myers Squibb accounts for 0.6% of SG Americas Securities LLC’s portfolio, making the stock its 23rd biggest position. SG Americas Securities LLC’s holdings in Bristol Myers Squibb were worth $540,393,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Norges Bank purchased a new position in shares of Bristol Myers Squibb in the fourth quarter worth $1,947,272,000. AQR Capital Management LLC boosted its position in Bristol Myers Squibb by 172.6% during the 4th quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company’s stock valued at $1,391,485,000 after buying an additional 16,332,924 shares during the period. Bank of New York Mellon Corp grew its holdings in Bristol Myers Squibb by 47.0% in the 4th quarter. Bank of New York Mellon Corp now owns 24,495,875 shares of the biopharmaceutical company’s stock worth $1,321,308,000 after acquiring an additional 7,837,485 shares during the last quarter. Geode Capital Management LLC grew its holdings in Bristol Myers Squibb by 13.1% in the 4th quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock worth $2,837,026,000 after acquiring an additional 6,084,046 shares during the last quarter. Finally, Man Group plc increased its position in shares of Bristol Myers Squibb by 280.4% in the second quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock valued at $345,594,000 after acquiring an additional 5,503,391 shares during the period. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Trading Up 0.2%

NYSE:BMY opened at $54.10 on Monday. The company has a 50-day moving average price of $57.34 and a 200-day moving average price of $57.15. The stock has a market cap of $110.48 billion, a price-to-earnings ratio of 15.20, a P/E/G ratio of 0.15 and a beta of 0.24. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The company had revenue of $11.49 billion for the quarter, compared to analysts’ expectations of $10.93 billion. During the same quarter in the previous year, the company earned $1.80 earnings per share. Bristol Myers Squibb’s quarterly revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities analysts predict that Bristol Myers Squibb Company will post 6.32 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be issued a dividend of $0.63 per share. The ex-dividend date is Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.7%. Bristol Myers Squibb’s dividend payout ratio is 70.79%.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on BMY shares. Bank of America lowered their price objective on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating for the company in a research note on Thursday, April 9th. Guggenheim restated a “buy” rating and set a $72.00 price target on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bristol Myers Squibb in a research report on Monday, March 23rd. Piper Sandler reiterated an “overweight” rating and issued a $75.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. Finally, HSBC lifted their price objective on Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a research report on Tuesday, March 17th. Eight investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Bristol Myers Squibb currently has a consensus rating of “Hold” and an average target price of $61.31.

Insider Activity

In other news, EVP David V. Elkins sold 30,000 shares of the stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the transaction, the executive vice president owned 159,248 shares of the company’s stock, valued at approximately $9,820,824.16. This represents a 15.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.